SEC Form 4 · accession 0000911916-15-000162
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas P. Mathers
Officer — Chief Executive Officer · Director
Period of report
May 5, 2015
Accepted (ET)
May 7, 2015 · 12:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $10.00 | May 5, 2015 | A | 360,508 | A | — | May 5, 2025 | Common Stock | 360,508 | 360,508 | D |
| Restricted Stock UnitsF2,F3 | — | May 5, 2015 | A | 360,508 | A | — | — | Common Stock | 360,508 | 360,508 | D |
Explanation of responses
- F1Options vest as follows: 50% of the shares vest on November 5, 2015; 12.5% of the shares vest on May 5, 2016; and the remaining shares vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- F3RSUs vest as follows: 50% of the RSUs vest on November 5, 2015; 12.5% of the RSUs vest on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.